Abbott Laboratories
ABT · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 43.65B | 22.32B | 8.36B | 6.93B | 3.94 |
| 2023 FY | 40.11B | 20.04B | 6.44B | 5.72B | 3.30 |
| 2024 FY | 41.95B | 21.33B | 6.83B | 13.40B | 7.67 |
| 2025 FY | 44.33B | 24.61B | 8.05B | 6.52B | 3.74 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 74.44B | 37.53B | 9.88B | 17.95B | 36.69B |
| 2023 FY | 73.21B | 34.39B | 6.90B | 15.87B | 38.60B |
| 2024 FY | 81.41B | 33.51B | 7.62B | 15.28B | 47.66B |
| 2025 FY | 86.71B | 33.94B | 8.52B | 15.07B | 52.13B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 9.58B | -1.78B | 7.80B | -3.31B | 83.00M |
| 2023 FY | 7.26B | -2.20B | 5.06B | -3.56B | -2.99B |
| 2024 FY | 8.56B | -2.21B | 6.35B | -3.84B | 720.00M |
| 2025 FY | 9.57B | -2.17B | 7.40B | -4.12B | 906.00M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 192.46B | 200.53B | — | — | — |
| 2023 FY | 190.87B | 199.85B | — | — | — |
| 2024 FY | 195.87B | 203.53B | — | — | — |
| 2025 FY | 218.88B | 225.43B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q3 | 11.37B | 6.34B | 2.06B | 1.64B | 0.94 |
| 2025 Q4 | 11.46B | 6.54B | 2.25B | 1.78B | 1.02 |
| 2026 Q1 | 11.16B | 6.28B | 1.84B | 1.08B | 0.62 |
| 2026 Q2 | 12.59B | 7.30B | 1.78B | 928.00M | 0.53 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 84.00B | 33.17B | 6.95B | 13.44B | 50.57B |
| 2025 Q3 | 84.18B | 32.92B | 7.51B | 12.94B | 50.95B |
| 2025 Q4 | 86.71B | 33.94B | 8.52B | 15.07B | 52.13B |
| 2026 Q1 | 110.43B | 57.73B | 6.80B | 34.05B | 52.06B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 2.05B | -502.00M | 1.55B | -1.03B | 419.00M |
| 2025 Q3 | 2.79B | -496.00M | 2.29B | -1.03B | 560.00M |
| 2025 Q4 | 3.32B | -689.00M | 2.63B | -1.03B | 1.01B |
| 2026 Q1 | 1.32B | -399.00M | 916.00M | -1.10B | -1.72B |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q3 | 234.26B | 239.69B | — | — | — |
| 2025 Q4 | 218.88B | 225.43B | — | — | — |
| 2026 Q1 | 179.36B | 206.60B | — | — | — |
| 2026-06-30 | — | — | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |